These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12228202)

  • 1. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
    Galbraith SM; Rustin GJ; Lodge MA; Taylor NJ; Stirling JJ; Jameson M; Thompson P; Hough D; Gumbrell L; Padhani AR
    J Clin Oncol; 2002 Sep; 20(18):3826-40. PubMed ID: 12228202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
    Galbraith SM; Lodge MA; Taylor NJ; Rustin GJ; Bentzen S; Stirling JJ; Padhani AR
    NMR Biomed; 2002 Apr; 15(2):132-42. PubMed ID: 11870909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
    McKeage MJ; Fong P; Jeffery M; Baguley BC; Kestell P; Ravic M; Jameson MB
    Clin Cancer Res; 2006 Mar; 12(6):1776-84. PubMed ID: 16551862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [MR-Imaging of lower leg muscle perfusion].
    Leppek R; Hoos O; Sattler A; Kohle S; Azzam S; Al Haffar I; Keil B; Ricken P; Klose KJ; Alfke H
    Herz; 2004 Feb; 29(1):32-46. PubMed ID: 14968340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
    McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP
    Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
    Seshadri M; Bellnier DA; Cheney RT
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1198-207. PubMed ID: 18954713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
    Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
    J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
    Jameson MB; Thompson PI; Baguley BC; Evans BD; Harvey VJ; Porter DJ; McCrystal MR; Small M; Bellenger K; Gumbrell L; Halbert GW; Kestell P;
    Br J Cancer; 2003 Jun; 88(12):1844-50. PubMed ID: 12799625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
    Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses.
    Ng CS; Raunig DL; Jackson EF; Ashton EA; Kelcz F; Kim KB; Kurzrock R; McShane TM
    AJR Am J Roentgenol; 2010 Feb; 194(2):W134-40. PubMed ID: 20093564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA.
    Barbera M; Kettunen MI; Caputo A; Hu DE; Gobbi S; Brindle KM; Carrara M
    Int J Oncol; 2009 Jan; 34(1):273-9. PubMed ID: 19082498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivascular therapy of cancer: DMXAA.
    Baguley BC
    Lancet Oncol; 2003 Mar; 4(3):141-8. PubMed ID: 12623359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Siemann DW; Overgaard J; Horsman MR
    Radiat Res; 2001 Nov; 156(5 Pt 1):503-9. PubMed ID: 11604063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Wilson WR; Li AE; Cowan DS; Siim BG
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):905-8. PubMed ID: 9845119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.